Comprehensive Management of Type 2 Diabetes in Gastric Cancer Patients

Research has identified the critical need for stage-specific glycemic management in patients with gastric cancer undergoing surgery. According to a recent study published in Gastric Cancer, a comprehensive approach to glycemic care is essential for improving metabolic and oncologic outcomes. This includes predicting type 2 diabetes remission, evaluating antidiabetic medications, and considering their adverse event profiles during the preoperative phase. The study highlights the importance of Roux-en-Y reconstructions and oncometabolic surgery as promising strategies for managing type 2 diabetes in these patients.

Key Takeaways:

• A comprehensive, stage-specific approach to glycemic care is crucial for improving both metabolic and oncologic outcomes in patients with gastric cancer.
• Preoperative phase strategies include predicting type 2 diabetes remission, evaluating antidiabetic medications, and considering their adverse event profiles.
• Roux-en-Y reconstructions are associated with better type 2 diabetes remission rates than Billroth I/II reconstructions due to enhanced glucose metabolism.
• Oncometabolic surgery, which integrates oncologic treatment with metabolic benefits, has gained attention as a promising strategy for managing type 2 diabetes in gastric cancer patients.
• Postoperative phase strategies include glucose monitoring, individualized medication adjustments, weight management, and patient education to maintain remission and prevent relapse.
• The study emphasizes the importance of a multidisciplinary approach to managing type 2 diabetes in gastric cancer patients.
• Metformin and sodium-glucose cotransporter 2 inhibitors may help prevent type 2 diabetes progression and gastric cancer advancement.
• The considerable effects of gastrectomy and reconstruction on glucose levels led to the development of oncometabolic surgery.

Statistics:

• Type 2 diabetes remission rates are higher with Roux-en-Y reconstructions compared to Billroth I/II reconstructions (84% vs. 20%).
• Metformin and sodium-glucose cotransporter 2 inhibitors have shown potential in preventing type 2 diabetes progression and gastric cancer advancement.
• Postoperative glucose monitoring is essential for maintaining remission and preventing relapse in type 2 diabetes patients.
• Individualized medication adjustments are crucial for managing type 2 diabetes in gastric cancer patients.

Sources:

• NewsRx. Findings on Type 2 Diabetes Reported by Researchers at Korea University College of Medicine (Type 2 diabetes in patients undergoing gastric cancer surgery: areas requiring disease-specific glycemic management). Cancer Weekly. October 14, 2025; p 182.
• Gastric Cancer, 2025.